Screener
Sutro Biopharma STRO Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Sutro Biopharma’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224170
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Interest income | 1,635 | 3,189 |
| Non-cash interest expense related to the sale of future royalties | (9,467) | (9,344) |
| Interest and other income (expense), net | (1,011) | (1,292) |
| Loss before provision for income taxes | (38,499) | (75,961) |
| (Benefit) from / provision for income taxes | (15) | 7 |
| Net loss | $(38,484) | $(75,968) |
| Net loss per share, basic and diluted | $(2.94) | $(9.08) |
| Weighted-average shares used in computing basic and diluted net loss per share | 13,082,355 | 8,364,294 |
Item 1. Financial Statements.
FAQ
- What is Sutro Biopharma's shares (diluted)?
- Sutro Biopharma (STRO) reported shares (diluted) of 13.1M in Q1 2026.
- How has Sutro Biopharma's shares (diluted) changed year-over-year?
- Sutro Biopharma's shares (diluted) increased by 56.4% year-over-year, from 8.4M to 13.1M.
- What is the long-term trend for Sutro Biopharma's shares (diluted)?
- Over 4 years (2021 to 2025), Sutro Biopharma's shares (diluted) has grown at a 0.3% compound annual growth rate (CAGR), from 184.3M to 186.3M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Sutro Biopharma's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude